Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Sold by Jane Street Group LLC

Jane Street Group LLC lowered its stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 75.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 82,727 shares of the biotechnology company's stock after selling 252,282 shares during the period. Jane Street Group LLC owned approximately 0.12% of Aclaris Therapeutics worth $95,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of ACRS. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Aclaris Therapeutics during the second quarter valued at about $119,000. Assenagon Asset Management S.A. bought a new position in Aclaris Therapeutics during the 3rd quarter valued at approximately $214,000. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Aclaris Therapeutics by 187.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 332,406 shares of the biotechnology company's stock worth $382,000 after buying an additional 216,826 shares during the period. Jacobs Levy Equity Management Inc. bought a new stake in shares of Aclaris Therapeutics in the 3rd quarter worth approximately $1,053,000. Finally, Trium Capital LLP increased its stake in shares of Aclaris Therapeutics by 1.1% during the third quarter. Trium Capital LLP now owns 1,912,990 shares of the biotechnology company's stock valued at $2,200,000 after buying an additional 20,940 shares during the period. Institutional investors own 98.34% of the company's stock.

Aclaris Therapeutics Trading Up 0.4 %

Shares of NASDAQ:ACRS traded up $0.01 on Wednesday, reaching $2.51. The company had a trading volume of 516,113 shares, compared to its average volume of 1,176,957. The firm has a market capitalization of $179.29 million, a PE ratio of -4.83 and a beta of 0.54. The firm's 50 day simple moving average is $3.09 and its 200-day simple moving average is $1.91. Aclaris Therapeutics, Inc. has a 52-week low of $0.95 and a 52-week high of $5.17.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.03). Aclaris Therapeutics had a negative return on equity of 40.26% and a negative net margin of 136.65%. The business had revenue of $4.35 million during the quarter, compared to analyst estimates of $8.31 million. As a group, equities research analysts predict that Aclaris Therapeutics, Inc. will post -0.75 earnings per share for the current year.

Insider Buying and Selling at Aclaris Therapeutics

In related news, Director Anand Mehra acquired 666,666 shares of Aclaris Therapeutics stock in a transaction that occurred on Tuesday, November 19th. The shares were purchased at an average cost of $2.25 per share, for a total transaction of $1,499,998.50. Following the acquisition, the director now owns 710,030 shares in the company, valued at approximately $1,597,567.50. This represents a 1,537.37 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 6.40% of the company's stock.

Wall Street Analysts Forecast Growth

ACRS has been the subject of a number of research analyst reports. Jefferies Financial Group raised Aclaris Therapeutics from a "hold" rating to a "buy" rating and raised their price target for the stock from $2.00 to $7.00 in a research note on Tuesday, November 19th. StockNews.com raised Aclaris Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday, November 15th. Piper Sandler upgraded shares of Aclaris Therapeutics from a "neutral" rating to an "overweight" rating and boosted their price objective for the stock from $3.00 to $13.00 in a report on Monday, November 18th. HC Wainwright upgraded shares of Aclaris Therapeutics from a "neutral" rating to a "buy" rating and set a $20.00 target price on the stock in a research note on Monday, December 23rd. Finally, Leerink Partners raised Aclaris Therapeutics from a "market perform" rating to an "outperform" rating and raised their target price for the stock from $2.00 to $7.00 in a research report on Tuesday, November 19th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Aclaris Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $11.00.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.